Shopping Cart
Remove All
Your shopping cart is currently empty
Sabizabulin (ABI-231) is a potent, orally bioavailable α- and β-tubulin inhibitor that is active against melanoma and prostate cancer cell lines. Sabizabulin inhibits tumor growth and metastatic phenotypes of cervical cancer cells by targeting HPV E6 and E7 and is also being studied in prostate cancer.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $73 | In Stock | In Stock | |
| 2 mg | $106 | In Stock | In Stock | |
| 5 mg | $176 | In Stock | In Stock | |
| 10 mg | $283 | In Stock | In Stock | |
| 25 mg | $542 | In Stock | In Stock | |
| 50 mg | $893 | - | In Stock | |
| 100 mg | $1,470 | - | In Stock | |
| 200 mg | $1,980 | - | In Stock |
| Description | Sabizabulin (ABI-231) is a potent, orally bioavailable α- and β-tubulin inhibitor that is active against melanoma and prostate cancer cell lines. Sabizabulin inhibits tumor growth and metastatic phenotypes of cervical cancer cells by targeting HPV E6 and E7 and is also being studied in prostate cancer. |
| In vitro | METHODS: BT474 and SKBR3 cells were treated with Sabizabulin (ABI-231) (4, 8, 12, 16 nM), and cell growth inhibition was measured by MTS assay. RESULTS Sabizabulin (ABI-231) significantly inhibited the growth of BT474 and SKBR3 cells in a concentration-dependent manner with IC50 values of 9.07 and 8.18 nM, respectively, and had low cytotoxicity. [1] |
| In vivo | METHODS: Sabizabulin (ABI-231) (17 mg/kg/20 mg/kg, oral, three weeks) was used to treat BT474 xenograft/HCI-12 PDX model mice and its therapeutic effect was observed. RESULTS Sabizabulin (ABI-231) significantly reduced the tumor volume and tumor wet weight of terminal BT474 xenograft mice, inhibited tumor growth and suppressed lung metastasis in HCI-12 PDX model mice. [1] |
| Synonyms | VERU-111, ABI-231 |
| Molecular Weight | 377.39 |
| Formula | C21H19N3O4 |
| Cas No. | 1332881-26-1 |
| Smiles | COc1cc(cc(OC)c1OC)C(=O)c1c[nH]c(n1)-c1c[nH]c2ccccc12 |
| Relative Density. | 1.306 g/cm3 (Predicted) |
| Color | Yellow |
| Appearance | Solid |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 50 mg/mL (132.49 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (5.3 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.